Related Experiment Videos
Therapeutic considerations for the malignant carcinoid syndrome
1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
Acta Oncologica (Stockholm, Sweden)
|January 1, 1989
Summary
This review summarizes carcinoid syndrome, emphasizing tailored treatments based on symptom severity. Somatostatin analogues are highlighted as crucial for managing severe symptoms and carcinoid crisis.
Area of Science:
- Oncology
- Endocrinology
Background:
- Carcinoid syndrome arises from neuroendocrine tumors.
- It presents with diverse symptomatology and potential organ dysfunction.
Purpose of the Study:
- To review the symptomatology and pathophysiology of carcinoid syndrome.
- To outline current and potential therapeutic strategies.
Main Methods:
- Literature review of carcinoid syndrome.
- Analysis of treatment options based on disease severity.
Main Results:
- Treatment should be individualized based on symptom intensity and organ impact.
- Mild cases may only require symptomatic relief for diarrhea.
- Severe cases warrant aggressive therapies including cytotoxic drugs, interferon, somatostatin analogues, or hepatic artery occlusion.
Conclusions:
- Appropriate treatment selection is key for managing carcinoid syndrome.
- Somatostatin analogues are particularly effective for severe symptoms and life-threatening carcinoid crisis.